Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol in pediatric Crohn's disease
NCT04643483Phase 3Withdrawn
- Sponsor
- UCB
- Start
- Jun 2021
- Primary completion
- Sep 2023
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
01
Overview
A Phase 3 trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Planned start Jun 2021; status: withdrawn.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04643483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643483.